← Leaderboards
Albert B Deleo
University Of Pittsburgh At Pittsburgh
$2,587,400
Attributed
$2,587,400
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $405.5K · FY2005–08$500K$375K$250K$125K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,587,400 · 4
By mechanism
P50$1,244,579 · 2
P01$842,013 · 1
P30$500,808 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jennifer R Grandis$109,711,044
- Roy A Mariuzza$20,943,458
- Donald L Trump$24,661,732
- Theresa L. Whiteside$29,550,469
- John Munn Kirkwood$15,450,309
Others in their field
Top investigators on “P53 Gene /Protein”
- Carol Prives · Icahn School Of Medicine At Mount Sinai$12,538,956
- Margaret R. Wrensch · University Of California San Francisco$6,944,039
- Andrei V Gudkov · University Of Illinois At Chicago$6,669,890
- Tyler E Jacks · Massachusetts Institute Of Technology$5,782,860
- Timothy J Yeatman · University Of South Florida$5,430,738
- Lawrence A. Donehower · Baylor College Of Medicine$4,852,912
Research focus
P53 Gene /ProteinNeoplasm /Cancer VaccineNeoplasm /Cancer GeneticsHuman SubjectSquamous Cell CarcinomaCytotoxic T LymphocyteImmunizationEpitope MappingMouth NeoplasmsDendritic CellsVaccine DevelopmentBiomedical FacilityTumor AntigensPatient Oriented ResearchMonoclonal AntibodyNeoplasm /Cancer ImmunologyHybridomasNeoplasm /Cancer ImmunotherapyAntigen PresentationCell LineMhc Class Ii AntigenHuman Therapy EvaluationMhc Class I AntigenCytosol
Grant awards (16)
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHN$405,477
P50 · FY2008 · CA · contact PI
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHN$377,462
P50 · FY2007 · CA · contact PI
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHN$153,880
P50 · FY2006 · CA · contact PI
Development of P53-Based Vaccines for Oral Cancer$146,616
P01 · FY2006 · DE · contact PI
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHN$153,880
P50 · FY2005 · CA
Development of P53-Based Vaccines for Oral Cancer$142,346
P01 · FY2005 · DE
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHN$153,880
P50 · FY2004 · CA
Development of P53-Based Vaccines for Oral Cancer$138,199
P01 · FY2004 · DE
Development of P53-Based Vaccines for Oral Cancer$134,173
P01 · FY2003 · DE
Core--Hybridoma$250,404
P30 · FY2002 · CA
Development of P53-Based Vaccines for Oral Cancer$130,265
P01 · FY2002 · DE
Core--Hybridoma$250,404
P30 · FY2001 · CA
DEVELOPMENT OF P53 BASED VACCINES FOR ORAL CARCINOMA$75,207
P01 · FY2001 · DE
Core--Hybridoma$0
P30 · FY2001 · CA
DEVELOPMENT OF P53 BASED VACCINES FOR ORAL CARCINOMA$75,207
P01 · FY2000 · DE
Core--Hybridoma$0
P30 · FY2000 · CA